A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma

Drug Category : Array
Conference Category : Array
Lead Author : Ramchandran et al.
Published Date : 05/12/2016
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/ASH%202016%20Ramchandren%20Final.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top